Assignee: Allergan Sales, Inc.

Location: Irvine, CA
No. of patents: 177

Browse patents
Browse applications

Number	Title	Issue Date
6869610	Pain treatment by peripheral administration of a neurotoxin Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin. ...	03/22/2005
6645496	Method for treating tardive dyskinesia with Botulinum toxin type B A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulin...	11/11/2003
6641834	Compositions containing alpha-2-adrenergic agonist components Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components...	11/04/2003
6548497	Methods of reducing non-inflammatory pain Methods for reducing non-inflammatory pain caused by injuries and traumas include administering to a mammal eye having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an ...	04/15/2003
6545182	Methods and compositions for modulating alpha adrenergic receptor activity Methods and compositions for the treatment of pain using thiourea derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use....	04/08/2003
6534542	(2-hydroxy)ethyl-thioureas useful as modulators of 򳄫 adrenergic receptors Compounds of formula (i) and of formula (ii) ##STR1## wherein the symbols have the meaning disclosed in the specification, specifically or selectively modulate 򳄫 and/or 򳄬 adrenergic receptors in preference over ³...	03/18/2003
6534544	Methods of treatment with compounds having RAR଱ receptor specific or selective activity Retinoid compounds which act specifically or selectively on RAR଱ receptor subtypes in preference over RARଲ and RAR.GAMMA. receptor subtypes, possess desirable pharmaceutical properties associated with retinoids...	03/18/2003
6531599	Compounds having activity as inhibitors of cytochrome P450RAI Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##STR1##...	03/11/2003
6524580	Method for treating thyroid disorders A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a...	02/25/2003
6506399	Biodegradable botulinum toxin implant A controlled release system for multiphasic, in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time. The controlled release system can comprise a plurality of botulinum toxin incorporating polymeric mi...	01/14/2003
6447519	Apparatus for holding intraocular lenses and injectors, and methods for using same Apparatus for holding intraocular lenses and apparatus for holding intraocular lens injectors are provided which provide convenient and effective packaging systems for intraocular lenses and allow convenient and effective transfer of an intraocular lens t...	09/10/2002
6447785	Method for treating hypercalcemia A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a...	09/10/2002
6440460	Pharmaceutical compositions containing buffered ortho ester polymers A pharmaceutical composition for the controlled release of therapeutic agents from carboxylic acid ortho ester polymers contains a pharmaceutically acceptable salt of an acid, which together with the acid R1-COOH liberated from the decomposition of the or...	08/27/2002
6426358	Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na	07/30/2002
6423319	Methods for treating muscle injuries Methods for treating an injured muscle by local administration of a neurotoxin, such as a botulinum toxin, to promote healing and/or to reduce the pain associated with an injured muscle....	07/23/2002
6423074	Flexible irrigation/aspiration tip assembly for providing irrigation to an eye capsule and for aspirating fluid from the eye capsule A flexible tip I/A tip assembly includes an elongated sleeve for protecting an eye capsule wound through which the sleeve is inserted and for containing irrigation fluid. The sleeve includes a lumen therethrough and a nipple for removably coupling the elo...	07/23/2002
6420402	Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na	07/16/2002
6416765	Neurotoxin therapy for diabetes The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulin...	07/09/2002
6414022	Cyclopentane(ENE)heptenoic or heptenoic acids and derivatives thereof useful as therapeutic agents The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by ...	07/02/2002
6410591	3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a 3, 7 or 3 and 7 thia or oxa prostanoic acid deriv...	06/25/2002
6410544	Cholinergic agents in the treatment of presbyopia A method for increasing or decreasing parasympathetic/cholinergic/ciliary tonic contraction in order to restore the resting portion of the eye and allow normal positive and negative accommodation includes administering to a myopic or hyperopic presbyope....	06/25/2002
6407250	Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists The present invention provides novel compounds represented by the general formula I. ##STR1## wherein m is an integer of from 1 to 3; n is 0 or an integer of from 1 to 4; R is selected from the group consisting of CO2 H, CO2 R6...	06/18/2002
6406494	Moveable intraocular lens Intraocular lenses include an optic adapted to focus light toward a retina of an eye and a movement assembly coupled to the optic. In one embodiment, the optic has a far vision correction power and the movement assembly is adapted to cooperate with the ey...	06/18/2002
6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compo...	06/11/2002
6403638	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors Compounds having the formulas below, where R is H, lower alkyl, or a pharmaceutically acceptable salt, and where R1 represents i-propyl, t-butyl or n-butyl groups, have selective RXR retionoid agonist activity. ##STR1##...	06/11/2002
6399774	Compounds having activity as inhibitors of cytochrome P450RAI Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##STR1##...	06/04/2002
6394974	Power mode phaco Phacoemulsification apparatus includes a phacoemulsification handpiece having a needle and an electrical system for ultrasonically vibrating said needle along with a power source for providing electrical power to the handpiece electrical system. Irrigatio...	05/28/2002
6395878	Nucleic acid encoding a human EP prostaglandin receptor A gene encoding the HP4 human prostaglandin receptor is disclosed. The protein encoded by this gene exhibits significant sequence identity with other prostaglandin receptors. The HP4 receptor, when expressed in eukaryotic cells, is capable of binding pros...	05/28/2002
6395787	Ocular hypotensive lipids Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. ##STR1## In particular the compound PGF2଱ 1-etha...	05/28/2002
6387951	Compounds having activity as inhibitors of cytochrome P450RAI Compounds having Formulas 5 and 6 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##...	05/14/2002
6387892	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme...	05/14/2002
6388105	Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors Compounds of the formula ##STR1## Where the variables are defined as in the specification, are selective agonists of RXR retinoid receptors....	05/14/2002
6387950	Treatment of tumors with RAR଱ selective retinoid compounds in combination with other anti-tumor agents Compounds which are specific or selective agonists of RAR଱ receptors in preference over RARଲ and RARγ receptors, and particularly compounds of the formula ##STR1## where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acce...	05/14/2002
6383509	Biodegradable neurotoxin implant A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin....	05/07/2002
6380256	Compounds having activity as inhibitors of cytochrome P450RAI Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. ##STR1##...	04/30/2002
6380251	Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: ...	04/30/2002
6380250	Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: ...	04/30/2002
6380261	Calcium blockers to treat proliferative vitreoretinopathy Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreor...	04/30/2002
6376533	Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula ...	04/23/2002
6372226	Intraspinal botulinum toxin for treating pain Methods for treating pain by intrathecal administration to a human patient of a therapeutically effective amount of a neurotoxin such as botulinum toxin type A are disclosed....	04/16/2002

«First «Previous1 2 3 4 5 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Allergan Sales, Inc.